2008 Chinese heparin adulteration
2008 Chinese Heparin Adulteration
The 2008 Chinese Heparin Adulteration (pronunciation: 2008 Chinese Heparin Adulteration) refers to a significant incident in the pharmaceutical industry where the anticoagulant drug heparin, sourced from China, was found to be adulterated with a cheaper, synthetic substitute.
Etymology
The term "2008 Chinese Heparin Adulteration" is derived from the year the incident occurred (2008), the country where the adulterated heparin originated (China), and the act of adulteration, which refers to the process of making something poorer in quality by adding another substance.
Background
Heparin is a naturally occurring anticoagulant produced by various animals, including pigs. In 2008, it was discovered that a significant portion of the world's supply of heparin, which was sourced from China, had been adulterated with a synthetic substitute known as oversulfated chondroitin sulfate (OSCS). This adulteration led to severe adverse reactions in patients, including death in some cases.
Impact
The 2008 Chinese Heparin Adulteration had a significant impact on the pharmaceutical industry, leading to increased scrutiny of drug supply chains and the implementation of more stringent quality control measures. It also highlighted the risks associated with sourcing pharmaceutical ingredients from overseas, particularly from countries with less stringent regulatory oversight.
Related Terms
External links
- Medical encyclopedia article on 2008 Chinese heparin adulteration
- Wikipedia's article - 2008 Chinese heparin adulteration
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski